Drug intelligence / Profile preview

WJ08

Development stage: Preclinical
Lead developer: Wigen Biomedicine Technology
Modality: Small Molecules
Administration: Oral

Overview

WJ08 is a small molecule inhibitor specifically targeting the **KRAS G12D** mutation, developed by **Wigen Biomedicine Technology (Shanghai)**. KRAS G12D is a common oncogenic driver in various cancers, particularly pancreatic ductal adenocarcinoma (PDAC), colorectal cancer, and non-small cell lung adenocarcinomas. By binding to the mutant KRAS G12D protein, WJ08 aims to block downstream signaling pathways, such as the MAPK/ERK and PI3K/AKT pathways, which promote tumor cell proliferation and survival. The drug is currently in development for the treatment of advanced solid tumors harboring the G12D mutation.

Targets

KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)

Beyond the preview

Go deeper on WJ08.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WJ08.

Explore the full profile